Approvals & regulatory · first seen 3h ago, updated 3h ago

Prime Medicine’s PM-647 gains IND approval for AATD

1 outlet FDA

Prime Medicine Inc. has obtained IND approval from the FDA for PM-647, an investigational in vivo Prime Editor for α-1 antitrypsin deficiency (AATD). A first-in-human phase I/II trial will evaluate a one-time intravenous infusion of PM-647…

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

BioWorld Articles 3h ago
Prime Medicine’s PM-647 gains IND approval for AATD